PLOD2 and breast carcinoma: This observation of highly effective uninduced low-dose SKD-mediated PLOD2 silencing was also observed for another breast cancer cell line at day 2 (MCF-7, Supplementary Figure S6) and for days 10 and 20, time points of the transgenic MDA-MB-231 cells (Supplementary Figure S7A).